| Kelly Kilroy, | |
|
1401 Atlantic Ave, Atlantic City, NJ 08401-7022 | |
| (609) 572-6000 | |
| Not Available |
| Full Name | Kelly Kilroy |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Location | 1401 Atlantic Ave, Atlantic City, New Jersey |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578915989 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | 26NJ00662800 (New Jersey) | Primary |
| 163W00000X | Registered Nurse | 26NR13811900 (New Jersey) | Secondary |
| Entity Name | Atlanticare Health Services, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215987771 PECOS PAC ID: 7911810916 Enrollment ID: O20040719001204 |
News Archive
Previous studies have hypothesized that low levels of the enzyme thymidylate synthase (TS) likely mark patients who will benefit from the drug pemetrexed - but results have been inconclusive at best and at times contradictory. A University of Colorado Cancer Center study recently published in the Journal of Thoracic Oncology provides an explanation why: only in combination with high levels of a second enzyme, FPGS, does low TS predict response to pemetrexed in patients with malignant pleural mesothelioma.
Using a new assay method to study tumor cells, researchers at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center have found evidence of clonal evolution in chronic lymphocytic leukemia (CLL).
A key part of a medical patient's physical examination is performed through touch, but the doctor can only glean so much information from what he feels. That's why Temple University researchers have created a prototype device that will not only emulate human tactile sensation, but quantify it as well.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of Serum Amyloid P (Pentraxin-2) will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2011), being held November 4-8, 2011, in San Francisco, CA.
› Verified 7 days ago
| Entity Name | Ronald C. Gove, Md, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417919176 PECOS PAC ID: 9931102597 Enrollment ID: O20060821000327 |
News Archive
Previous studies have hypothesized that low levels of the enzyme thymidylate synthase (TS) likely mark patients who will benefit from the drug pemetrexed - but results have been inconclusive at best and at times contradictory. A University of Colorado Cancer Center study recently published in the Journal of Thoracic Oncology provides an explanation why: only in combination with high levels of a second enzyme, FPGS, does low TS predict response to pemetrexed in patients with malignant pleural mesothelioma.
Using a new assay method to study tumor cells, researchers at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center have found evidence of clonal evolution in chronic lymphocytic leukemia (CLL).
A key part of a medical patient's physical examination is performed through touch, but the doctor can only glean so much information from what he feels. That's why Temple University researchers have created a prototype device that will not only emulate human tactile sensation, but quantify it as well.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of Serum Amyloid P (Pentraxin-2) will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2011), being held November 4-8, 2011, in San Francisco, CA.
› Verified 7 days ago
| Entity Name | Regenerative Medicine Of South Jersey Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992342109 PECOS PAC ID: 5799111860 Enrollment ID: O20200210000019 |
News Archive
Previous studies have hypothesized that low levels of the enzyme thymidylate synthase (TS) likely mark patients who will benefit from the drug pemetrexed - but results have been inconclusive at best and at times contradictory. A University of Colorado Cancer Center study recently published in the Journal of Thoracic Oncology provides an explanation why: only in combination with high levels of a second enzyme, FPGS, does low TS predict response to pemetrexed in patients with malignant pleural mesothelioma.
Using a new assay method to study tumor cells, researchers at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center have found evidence of clonal evolution in chronic lymphocytic leukemia (CLL).
A key part of a medical patient's physical examination is performed through touch, but the doctor can only glean so much information from what he feels. That's why Temple University researchers have created a prototype device that will not only emulate human tactile sensation, but quantify it as well.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of Serum Amyloid P (Pentraxin-2) will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2011), being held November 4-8, 2011, in San Francisco, CA.
› Verified 7 days ago
| Entity Name | Active Health Marmora Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629707369 PECOS PAC ID: 2961853122 Enrollment ID: O20240111004280 |
News Archive
Previous studies have hypothesized that low levels of the enzyme thymidylate synthase (TS) likely mark patients who will benefit from the drug pemetrexed - but results have been inconclusive at best and at times contradictory. A University of Colorado Cancer Center study recently published in the Journal of Thoracic Oncology provides an explanation why: only in combination with high levels of a second enzyme, FPGS, does low TS predict response to pemetrexed in patients with malignant pleural mesothelioma.
Using a new assay method to study tumor cells, researchers at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center have found evidence of clonal evolution in chronic lymphocytic leukemia (CLL).
A key part of a medical patient's physical examination is performed through touch, but the doctor can only glean so much information from what he feels. That's why Temple University researchers have created a prototype device that will not only emulate human tactile sensation, but quantify it as well.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of Serum Amyloid P (Pentraxin-2) will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2011), being held November 4-8, 2011, in San Francisco, CA.
› Verified 7 days ago
| Entity Name | Active Health Marlton Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265161905 PECOS PAC ID: 4486097706 Enrollment ID: O20240202003806 |
News Archive
Previous studies have hypothesized that low levels of the enzyme thymidylate synthase (TS) likely mark patients who will benefit from the drug pemetrexed - but results have been inconclusive at best and at times contradictory. A University of Colorado Cancer Center study recently published in the Journal of Thoracic Oncology provides an explanation why: only in combination with high levels of a second enzyme, FPGS, does low TS predict response to pemetrexed in patients with malignant pleural mesothelioma.
Using a new assay method to study tumor cells, researchers at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center have found evidence of clonal evolution in chronic lymphocytic leukemia (CLL).
A key part of a medical patient's physical examination is performed through touch, but the doctor can only glean so much information from what he feels. That's why Temple University researchers have created a prototype device that will not only emulate human tactile sensation, but quantify it as well.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of Serum Amyloid P (Pentraxin-2) will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2011), being held November 4-8, 2011, in San Francisco, CA.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kelly Kilroy, 300 Church Rd, Marmora, NJ 08223-1253 Ph: (609) 425-4321 | Kelly Kilroy, 1401 Atlantic Ave, Atlantic City, NJ 08401-7022 Ph: (609) 572-6000 |
News Archive
Previous studies have hypothesized that low levels of the enzyme thymidylate synthase (TS) likely mark patients who will benefit from the drug pemetrexed - but results have been inconclusive at best and at times contradictory. A University of Colorado Cancer Center study recently published in the Journal of Thoracic Oncology provides an explanation why: only in combination with high levels of a second enzyme, FPGS, does low TS predict response to pemetrexed in patients with malignant pleural mesothelioma.
Using a new assay method to study tumor cells, researchers at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center have found evidence of clonal evolution in chronic lymphocytic leukemia (CLL).
A key part of a medical patient's physical examination is performed through touch, but the doctor can only glean so much information from what he feels. That's why Temple University researchers have created a prototype device that will not only emulate human tactile sensation, but quantify it as well.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of Serum Amyloid P (Pentraxin-2) will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2011), being held November 4-8, 2011, in San Francisco, CA.
› Verified 7 days ago
Mr. Matthew R Soos, APN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1925 Pacific Ave, Atlantic City, NJ 08401 Phone: 609-572-8600 | |
Helene E Fedele, ACNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 2922 Atlantic Ave, 2nd Floor, Atlantic City, NJ 08401 Phone: 609-437-2020 Fax: 609-345-4290 | |
Nediya Griffith, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2009 Bacharach Blvd, Atlantic City, NJ 08401 Phone: 609-344-5714 Fax: 609-575-6033 | |
Marisa B Scibilia, APN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1925 Pacific Ave., Atlantic City, NJ 08401 Phone: 609-441-8023 | |
Debra Walters-olaru, APN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 801 Boardwalk, Showboat Wellness Center, Atlantic City, NJ 08401 Phone: 609-343-4003 | |
Kelli L Gramlich, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1925 Pacific Ave, Atlantic City, NJ 08401 Phone: 609-441-8023 | |
Elaina M Nixon, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1925 Pacific Ave, Atlantic City, NJ 08401 Phone: 609-441-8146 |